Literature DB >> 16214108

Targeted inhibition of p38alpha MAPK suppresses tumor-associated endothelial cell migration in response to hypericin-based photodynamic therapy.

Nico Hendrickx1, Michael Dewaele, Esther Buytaert, Glenn Marsboom, Stefan Janssens, Maurits Van Boven, Jackie R Vandenheede, Peter de Witte, Patrizia Agostinis.   

Abstract

Photodynamic therapy (PDT) is an established anticancer modality and hypericin is a promising photosensitizer for the treatment of bladder tumors. We show that exposure of bladder cancer cells to hypericin PDT leads to a rapid rise in the cytosolic calcium concentration which is followed by the generation of arachidonic acid by phospholipase A2 (PLA2). PLA2 inhibition significantly protects cells from the PDT-induced intrinsic apoptosis and attenuates the activation of p38 MAPK, a survival signal mediating the up-regulation of cyclooxygenase-2 that converts arachidonic acid into prostanoids. Importantly, inhibition of p38alpha MAPK blocks the release of vascular endothelial growth factor and suppresses tumor-promoted endothelial cell migration, a key step in angiogenesis. Hence, targeted inhibition of p38alpha MAPK could be therapeutically beneficial to PDT, since it would prevent COX-2 expression, the inducible release of growth and angiogenic factors by the cancer cells, and cause an increase in the levels of free arachidonic acid, which promotes apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214108     DOI: 10.1016/j.bbrc.2005.09.135

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 2.  Mechanisms of resistance to photodynamic therapy.

Authors:  A Casas; G Di Venosa; T Hasan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

3.  PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress.

Authors:  T Verfaillie; N Rubio; A D Garg; G Bultynck; R Rizzuto; J-P Decuypere; J Piette; C Linehan; S Gupta; A Samali; P Agostinis
Journal:  Cell Death Differ       Date:  2012-06-15       Impact factor: 15.828

Review 4.  Strategies for Improving Photodynamic Therapy Through Pharmacological Modulation of the Immediate Early Stress Response.

Authors:  Daniel J de Klerk; Mark J de Keijzer; Lionel M Dias; Jordi Heemskerk; Lianne R de Haan; Tony G Kleijn; Leonardo P Franchi; Michal Heger
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Hypericins as potential leads for new therapeutics.

Authors:  Anastasia Karioti; Anna Rita Bilia
Journal:  Int J Mol Sci       Date:  2010-02-04       Impact factor: 5.923

6.  Intracellular free calcium mediates glioma cell detachment and cytotoxicity after photodynamic therapy.

Authors:  Xin Hong; Feng Jiang; Steven N Kalkanis; Zheng Gang Zhang; Xuepeng Zhang; Xuguang Zheng; Hao Jiang; Michael Chopp
Journal:  Lasers Med Sci       Date:  2009-02-07       Impact factor: 3.161

7.  Hypericin-mediated photodynamic therapy induces apoptosis of myoloma SP2/0 cells depended on caspase activity in vitro.

Authors:  Junping Zhang; Linxiang Shao; Chunlin Wu; Hongfei Lu; Ruian Xu
Journal:  Cancer Cell Int       Date:  2014-12-19       Impact factor: 5.722

8.  The Influence of Hypericin-Mediated Photodynamic Therapy on Interleukin-8 and -10 Secretion in Colon Cancer Cells.

Authors:  Marta Kaleta-Richter; David Aebisher; Dagmara Jaworska; Zenon Czuba; Grzegorz Cieślar; Aleksandra Kawczyk-Krupka
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

9.  In vitro comparison of hypericin and 5-aminolevulinic acid-derived protoporphyrin IX for photodynamic inactivation of medulloblastoma cells.

Authors:  Rainer Ritz; Christian Scheidle; Susan Noell; Florian Roser; Martin Schenk; Klaus Dietz; Wolfgang S L Strauss
Journal:  PLoS One       Date:  2012-12-14       Impact factor: 3.240

10.  Enhancing photodynamyc therapy efficacy by combination therapy: dated, current and oncoming strategies.

Authors:  Ilaria Postiglione; Angela Chiaviello; Giuseppe Palumbo
Journal:  Cancers (Basel)       Date:  2011-06-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.